Clinical Trial Update: Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the immunogenicity and safety (reactogenicity) of a booster dose of GSK's DTPa-HBV-IPV/Hib vaccine, with results posted after completio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTPa-HBV-IPV/Hib vaccine (DTPa-HBV-IPV/Hib vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Diphtheria | Phase 2 | Status: COMPLETED | Results posted: 2017-06-26